Floatz logo

Therapeutic Asset Ratings

470 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Serplulimab
Newly Diagnosed MYC/BCL2 Double-expressor DLBCL
Sun Yat-sen UniversityP2CCC (53)
Serplulimab
Renal Cell Carcinoma
Sun Yat-sen UniversityP2CCC (53)
Sunvozertinib
Lung Cancer
Sun Yat-sen UniversityP2CCC (53)
Sunvozertinib
Mutation
Sun Yat-sen UniversityP2CCC (53)
Surufatinib
Non-Small Cell Lung Carcinoma
Sun Yat-sen UniversityP2CCC (53)
Surufatinib
Chemoradiotherapy
Sun Yat-sen UniversityP2CCC (53)
Surufatinib
Concurrent Chemoradiotherapy
Sun Yat-sen UniversityP2CCC (53)
Surufatinib
Consolidation Therapy
Sun Yat-sen UniversityP2CCC (53)
Surufatinib
Pancreatic Adenocarcinoma
Sun Yat-sen UniversityP2CCC (53)
Surufatinib
Surufatinib
Sun Yat-sen UniversityP2CCC (53)
Surufatinib
Tislelizumab
Sun Yat-sen UniversityP2CCC (53)
Surufatinib
Toripalimab
Sun Yat-sen UniversityP2CCC (53)
Theprubicin
Double Express Diffuse Large B-cell Lymphoma
Sun Yat-sen UniversityP2CCC (53)
Thymosin Alpha 1
Immune Checkpoint Inhibitor
Sun Yat-sen UniversityP2CCC (53)
Thymosin Alpha 1
Small-Cell Lung Cancer (SCLC)
Sun Yat-sen UniversityP2CCC (53)
Tisleizumab
Anti PD-1
Sun Yat-sen UniversityP2CCC (53)
Tislelizumab
Consolidation Therapy
Sun Yat-sen UniversityP2CCC (53)
Tislelizumab
Disitamab Vedotin
Sun Yat-sen UniversityP2CCC (53)
Tislelizumab
ERBB2 Mutation-Related Tumors
Sun Yat-sen UniversityP2CCC (53)
Tislelizumab
MCRC
Sun Yat-sen UniversityP2CCC (53)
Tislelizumab
RC48
Sun Yat-sen UniversityP2CCC (53)
Tislelizumab
Surufatinib
Sun Yat-sen UniversityP2CCC (53)
Toripalimab
Colorectal Cancer Liver Metastases
Sun Yat-sen UniversityP2CCC (53)
Toripalimab
Esophageal Small Cell Neuroendocrine Carcinoma
Sun Yat-sen UniversityP2CCC (53)
Toripalimab
First-line Treatment
Sun Yat-sen UniversityP2CCC (53)
Showing 251 to 275 of 470 assets
PreviousPage 11 of 19Next